Actively Recruiting
Evaluating ATTN201 Focused Ultrasound Targeting for Treating Depression, Anxiety, and OCD Using Adaptive Dose-Finding
Led by Attune Neurosciences Inc · Updated on 2026-10-27
300
Participants Needed
2
Research Sites
6 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and early effects of repeated low-intensity focused ultrasound LIFU stimulation using the ATTN201 device in adults with mild to moderate depression, anxiety, or obsessive-compulsive disorder. This double-blind, multi-site dose-finding study uses a crossover design where participants receive stimulation to different deep-brain targets to find optimal treatment parameters. Participants receive between 3 and 10 stimulation sessions spaced about one week apart. Each session delivers active ATTN201 stimulation targeted to one of seven brain areas, selected by a Bayesian optimization algorithm. The study has two stages the first explores all seven targets, then selects 3-5 targets for further optimization in the second stage. No sham or placebo is used, and participants and staff are blinded to target and settings. During participation, individuals undergo screening, baseline clinical assessments, brain MRI for targeting, and wear monitoring devices including a smart watch and optional ambulatory EEG. Clinical scales measuring depression, anxiety, and obsessive-compulsive symptoms are collected before each session and during follow-ups at 1 week, 2 weeks, and 3 months after the last stimulation. Researchers track brain activity, mood, sleep, and physical activity to assess outcomes and safety throughout the study, which may last several months.
CONDITIONS
Brief Title
Focused Ultrasound for Behavioral Health
Research Team
K
Keith Murphy, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here